|
Expression System |
CHO |
|
Aggregation |
< 5% as determined by SEC-HPLC |
|
Purity |
> 95% as determined by SDS-PAGE |
|
Sterility |
0.22 μm Filtered |
|
Clone |
sibeprenlimab |
|
Source/Isotype |
Human IgG2 Kappa |
|
Application |
Bioactivity-ELISA |
|
Specificity |
Detects APRIL |
|
Gene |
APRIL |
|
Other Names |
APRIL, TNFSF13, TALL-2, TRDL-1, CD256, TALL2, ZTNF2 |
|
Gene ID |
8741 (human) |
|
Background |
APRIL is a type II TNF superfamily membrane protein encoded by TNFSF13 (also TNFSF13A). It is expressed in various immune and some non-hematopoietic cells. It exists in membrane-bound and soluble forms (soluble via shedding). APRIL promotes B cell survival, maturation, differentiation, and immunoglobulin production; its dysregulation is linked to autoimmunity and certain hematologic cancers. APRIL binds primarily to TACI and BCMA receptors, activating canonical and noncanonical NF-κB and MAPK pathways. This upregulates anti-apoptotic genes (e.g., BCL2 family) and plasma cell differentiation factors, supporting long-lasting humoral responses. APRIL can cooperate with BAFF to modulate signaling. Dysregulated APRIL–receptor signaling is associated with autoimmunity, making it a therapeutic target in diseases like SLE and monoclonal gammopathies. |
|
Formulation |
Phosphate-buffered solution, pH 7.2-7.4. |
|
Endotoxin |
< 1 EU/mg, determined by LAL gel clotting assay
|
